[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610349":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":97,"collaborators":11,"id":99,"slug":11,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":11,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":11,"enrollmentInfo":107,"targetDuration":11,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Stemline Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: MEN2501 Dose Escalation","EXPERIMENTAL",null,[13],"Drug: MEN2501",{"label":15,"type":10,"description":11,"interventionNames":16},"Part B: MEN2501 Dose Expansion & Optimization",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","MEN2501","Oral tablet",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Medical Director","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Stemline Trials","CONTACT","1-877-332-7961","cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com",[34,47,57,67,77,87],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"Highlands Oncology Group","RECRUITING","Springdale","Arkansas","72762","United States",{"type":42,"coordinates":43},"Point",[44,45],-94.12881,36.18674,{"lat":45,"lon":44},{"facility":48,"status":36,"city":49,"state":50,"zip":51,"country":40,"cosmosGeoPoint":52,"geoPoint":56,"contacts":11},"Yale University","New Haven","Connecticut","06519",{"type":42,"coordinates":53},[54,55],-72.92816,41.30815,{"lat":55,"lon":54},{"facility":58,"status":36,"city":59,"state":60,"zip":61,"country":40,"cosmosGeoPoint":62,"geoPoint":66,"contacts":11},"Florida Cancer Specialists & Research Institute","Sarasota","Florida","34232",{"type":42,"coordinates":63},[64,65],-82.53065,27.33643,{"lat":65,"lon":64},{"facility":68,"status":36,"city":69,"state":70,"zip":71,"country":40,"cosmosGeoPoint":72,"geoPoint":76,"contacts":11},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":42,"coordinates":73},[74,75],-83.04575,42.33143,{"lat":75,"lon":74},{"facility":78,"status":36,"city":79,"state":80,"zip":81,"country":40,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"Mayo Clinic","Rochester","Minnesota","55905",{"type":42,"coordinates":83},[84,85],-92.4699,44.02163,{"lat":85,"lon":84},{"facility":88,"status":36,"city":89,"state":90,"zip":91,"country":40,"cosmosGeoPoint":92,"geoPoint":96,"contacts":11},"NEXT Virginia","Fairfax","Virginia","22031",{"type":42,"coordinates":93},[94,95],-77.30637,38.84622,{"lat":95,"lon":94},{"type":98,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610349",false,"NCT07226427","A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer","A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer","Key Inclusion Criteria:\n\n* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.\n\nKey Exclusion Criteria:\n\n* Participants with primary platinum-refractory disease.\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.","FEMALE","18 Years",{"count":108,"type":109},100,"ESTIMATED","INTERVENTIONAL",[112],"PHASE1","This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.",[115],"Platinum-resistant Ovarian Cancer",[20,117,118],"First-in-Human","Ovarian Cancer","2026-05-20",{"date":121,"type":122},"2026-05-26","ACTUAL",{"date":124,"type":122},"2026-01-10",{"date":126,"type":109},"2028-06-02",{"name":5,"class":6},6]